Are you considering cardiovascular risk in type 2 diabetes?

Training Video • AstraZeneca

About the CPD course

The treatment of type 2 diabetes (T2D) has evolved from blood glucose control being recognised as the main focus of management. The latest update to the NICE guidelines (NG28) has seen a paradigm shift in how T2D is managed; with the updated guideline recognising cardiovascular risk management as equally important as blood glucose control. This 8-minute video will take you through: How the treatment of T2D has changed since the last NICE guidelines came out in 2015 The impact the recommended updates in the latest NICE guidelines will have in the first-line treatment of T2D.

CPD Provider

AstraZeneca

View Profile

Send an enquiry

Full Name*

Email Address*

Contact Number*

Industry*

Your Enquiry*

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.